# BIOLOGICAL TESTING FACILITY - "CONTRACEPTIVE DRUG AND INTRAVAGINAL CONTRACEPTIVE DEVICE EVALUATION"

> **NIH NIH N01** · SRI INTERNATIONAL · 2020 · $700,037

## Abstract

The Contraception Research Branch (CRB) within the Eunice Kennedy Shriver National Institute of 
Child Health and Human Development (NICHD) supports research to develop compounds that can  disrupt 
 oogenesis,  spermatogenesis,  normal  ovulation,  sperm  maturation  and/or  function affording 
safe and effective contraceptives that can be implemented for men and/or women.  The Biological 
Testing Facility (BTF) is designed to permit rapid evaluation of new compositions-of- matter,  drug 
 formulations,  delivery  systems,  and  devices  for  contraceptive  activity.   The  BTF provides 
  overall  project  management  and  the  capabilities  to  support  all  phases  of  preclinical 
activities  pursuant  to  development  of  new  contraceptives  methods:  these  include,  but  are 
 not limited  to  in  vitro  and  in  vivo  assays,  plasma  and  microsomal  stability  studies,  
absorption, distribution,     metabolism,     excretion     (ADME),     toxicity,     
Pharmacokinetic     (PK)     and Pharmacodynamic   (PD)   profiling,   animal   activities   and   
studies,   manufacture   of   active pharmaceutical  ingredients  (APIs),  process  and  product  
development,  formulation,  clinical  lot production, preclinical enabling studies and associated 
tasks leading to the filing of investigational new  drug  (IND)  or   Investigational  Device  
Exemption  (IDE)  applications.   The  BTF  has  the capability to prepare compounds under current 
Good Manufacturing Practices (cGMP) to allow clinical evaluation.  The BTF has been working with 
the CORs for the Chemical Synthesis Facility and the CCTN and with investigators in the CCTN to 
develop and test the appropriate formation for clinical batches of the candidate compounds.  The 
Biological Testing Facility plays a critical role in the product development mission of the CRB.

## Key facts

- **NIH application ID:** 10271538
- **Project number:** 75N94020D00003-0-759402000003-1
- **Recipient organization:** SRI INTERNATIONAL
- **Principal Investigator:** TOUFAN PARMAN
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $700,037
- **Award type:** —
- **Project period:** 2020-09-22 → 2021-09-21

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10271538

## Citation

> US National Institutes of Health, RePORTER application 10271538, BIOLOGICAL TESTING FACILITY - "CONTRACEPTIVE DRUG AND INTRAVAGINAL CONTRACEPTIVE DEVICE EVALUATION" (75N94020D00003-0-759402000003-1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10271538. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*